

Supplementary Information

MicroRNA signature refine response prediction in CML

Raquel Alves^{1,2,3}, Ana Cristina Gonçalves^{1,2,3}, Joana Jorge^{1,2,3}, Gilberto Marques⁴, Dino Luís⁵, André B. Ribeiro^{2,5}, Paulo Freitas-Tavares⁵, Bárbara Oliveiros^{2,6}, António M. Almeida^{7,8} and Ana Bela Sarmiento-Ribeiro^{1,2,3,5*}

Supplementary Figures




Figure S1 – Ct variance of miR-16 in CML patients according the different comparative groups. The Ct value of miR-16 of CML patients at diagnosis according response levels (a). At follow-up measures, the Ct variance of this miR according to the number of TKI that patients were exposed (b), to *BCR-ABL1* values (c) and to molecular response rates (d). The results are represented as median with interquartile range. Any statistical difference was detected between groups.